Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Chevy Chase Trust Holdings LLC

Chevy Chase Trust Holdings LLC trimmed its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 2.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 178,955 shares of the medical equipment provider's stock after selling 4,394 shares during the period. Chevy Chase Trust Holdings LLC owned 0.08% of Hologic worth $11,054,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of HOLX. Norges Bank purchased a new stake in Hologic during the 4th quarter worth about $133,414,000. Boston Partners lifted its holdings in shares of Hologic by 81.0% in the 4th quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock valued at $257,959,000 after purchasing an additional 1,602,463 shares during the last quarter. Champlain Investment Partners LLC purchased a new stake in shares of Hologic in the 4th quarter valued at about $79,291,000. Redwood Wealth Management Group LLC purchased a new stake in shares of Hologic in the 1st quarter valued at about $3,534,000. Finally, Northern Trust Corp lifted its holdings in shares of Hologic by 26.9% in the 4th quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider's stock valued at $226,898,000 after purchasing an additional 668,086 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Price Performance

HOLX traded down $0.10 during trading on Friday, reaching $65.01. 3,320,131 shares of the stock were exchanged, compared to its average volume of 2,371,675. The business's 50 day moving average price is $59.85 and its two-hundred day moving average price is $64.14. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.24 and a quick ratio of 2.52. The company has a market capitalization of $14.49 billion, a price-to-earnings ratio of 27.43, a P/E/G ratio of 2.36 and a beta of 0.55. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 19.71% and a net margin of 13.83%. Hologic's quarterly revenue was down 1.2% compared to the same quarter last year. During the same period in the previous year, the business earned $1.03 earnings per share. As a group, equities research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Needham & Company LLC reissued a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Argus downgraded Hologic from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Citigroup dropped their price target on Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Royal Bank Of Canada dropped their price target on Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a research report on Friday, May 2nd. Finally, Morgan Stanley dropped their price target on Hologic from $77.00 to $65.00 and set an "equal weight" rating on the stock in a research report on Monday, May 5th. Twelve investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $77.42.

Insiders Place Their Bets

In related news, Director Martin D. Madaus acquired 5,445 shares of the firm's stock in a transaction that occurred on Wednesday, May 7th. The shares were acquired at an average price of $55.24 per share, with a total value of $300,781.80. Following the completion of the purchase, the director now directly owns 5,445 shares in the company, valued at approximately $300,781.80. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.88% of the stock is owned by company insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.